CCR5 Receptor Antagonists

"CCR5 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS.

Descriptor ID	D065100
MeSH Number(s)	D27.505.519.275 D27.505.954.122.388.077.088.104
Concept/Terms	CCR5 Receptor Antagonists CCR5 Receptor Antagonists Antagonists, CCR5 Receptor Receptor Antagonists, CCR5 CC Chemokine Receptor 5 Blockers Chemokine Co-receptor 5 Antagonists Chemokine Co receptor 5 Antagonists HIV-1 Fusion Coreceptor Antagonists HIV 1 Fusion Coreceptor Antagonists CC Chemokine Receptor 5 Antagonists CCR5 Receptor Blockers Blockers, CCR5 Receptor Receptor Blockers, CCR5

Below are MeSH descriptors whose meaning is more general than "CCR5 Receptor Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
CCR5 Receptor Antagonists [D27.505.519.275]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Anti-HIV Agents [D27.505.954.122.388.077.088]
CCR5 Receptor Antagonists [D27.505.954.122.388.077.088.104]

Below are MeSH descriptors whose meaning is related to "CCR5 Receptor Antagonists".

Below are MeSH descriptors whose meaning is more specific than "CCR5 Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CCR5 Receptor Antagonists" by people in this website by year, and whether "CCR5 Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2007 and 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2007	1	1	2
2011	0	2	2
2018	1	0	1
2019	1	0	1
2020	0	1	1
2024	0	1	1

Below are the most recent publications written about "CCR5 Receptor Antagonists" by people in Profiles.

Zikos J, Webb GM, Wu HL, Reed JS, Watanabe J, Usachenko JL, Shaqra AM, Schiffer CA, Van Rompay KKA, Sacha JB, Magnani DM. FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques. MAbs. 2024 Jan-Dec; 16(1):2406788.

View in: PubMed
Lowe PP, Morel C, Ambade A, Iracheta-Vellve A, Kwiatkowski E, Satishchandran A, Furi I, Cho Y, Gyongyosi B, Catalano D, Lefebvre E, Fischer L, Seyedkazemi S, Schafer DP, Szabo G. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations. J Neuroinflammation. 2020 Oct 09; 17(1):296.

View in: PubMed
Ambade A, Lowe P, Kodys K, Catalano D, Gyongyosi B, Cho Y, Iracheta-Vellve A, Adejumo A, Saha B, Calenda C, Mehta J, Lefebvre E, Vig P, Szabo G. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. Hepatology. 2019 03; 69(3):1105-1121.

View in: PubMed
Harel A, Horng S, Gustafson T, Ramineni A, Farber RS, Fabian M. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J Neurovirol. 2018 10; 24(5):652-655.

View in: PubMed
Schleifman EB, Bindra R, Leif J, del Campo J, Rogers FA, Uchil P, Kutsch O, Shultz LD, Kumar P, Greiner DL, Glazer PM. Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem Biol. 2011 Sep 23; 18(9):1189-98.

View in: PubMed
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011 Feb; 7(2):e1001303.

View in: PubMed
Repik A, Richards KH, Clapham PR. The promise of CCR5 antagonists as new therapies for HIV-1. Curr Opin Investig Drugs. 2007 Feb; 8(2):130-9.

View in: PubMed
Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, Mascola JR, Agopian K, Holm GH, Mehle A, Taylor J, Farzan M, Wang H, Ellery P, Willey SJ, Clapham PR, Wolinsky SM, Crowe SM, Gabuzda D. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007 May 25; 362(1):163-78.

View in: PubMed
Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 2005 Nov; 68(2):96-108.

View in: PubMed

People

Explore

Similar Concepts

Top Journals